Simulations Plus (NASDAQ:SLP) Price Target Raised to $37.00

Simulations Plus (NASDAQ:SLP) had its price target increased by KeyCorp from $35.00 to $37.00 in a report issued on Friday,Benzinga reports. KeyCorp currently has an overweight rating on the technology company’s stock.

Other research analysts have also issued research reports about the company. BTIG Research reduced their price objective on Simulations Plus from $60.00 to $50.00 and set a “buy” rating for the company in a research report on Thursday, October 24th. StockNews.com downgraded Simulations Plus from a “hold” rating to a “sell” rating in a report on Monday, November 4th. Stephens began coverage on shares of Simulations Plus in a research note on Friday, November 15th. They issued an “overweight” rating and a $39.00 price target on the stock. Finally, William Blair restated an “outperform” rating on shares of Simulations Plus in a research note on Wednesday, January 8th. One investment analyst has rated the stock with a sell rating, one has given a hold rating, five have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $49.40.

Simulations Plus Stock Performance

Shares of SLP opened at $33.78 on Friday. Simulations Plus has a fifty-two week low of $24.00 and a fifty-two week high of $51.22. The firm’s 50-day simple moving average is $29.95 and its two-hundred day simple moving average is $32.80. The stock has a market cap of $678.64 million, a PE ratio of 84.45 and a beta of 0.80.

Insider Transactions at Simulations Plus

In other news, Director Walter S. Woltosz sold 20,000 shares of the firm’s stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $31.76, for a total value of $635,200.00. Following the transaction, the director now directly owns 3,442,584 shares in the company, valued at $109,336,467.84. This trade represents a 0.58 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. Company insiders own 19.40% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of SLP. First Horizon Advisors Inc. increased its position in shares of Simulations Plus by 82.6% during the 3rd quarter. First Horizon Advisors Inc. now owns 818 shares of the technology company’s stock valued at $26,000 after purchasing an additional 370 shares during the last quarter. nVerses Capital LLC grew its position in Simulations Plus by 1,100.0% during the third quarter. nVerses Capital LLC now owns 1,200 shares of the technology company’s stock valued at $38,000 after buying an additional 1,100 shares during the period. Quantbot Technologies LP purchased a new stake in Simulations Plus during the third quarter valued at approximately $59,000. US Bancorp DE boosted its stake in shares of Simulations Plus by 37.0% during the 3rd quarter. US Bancorp DE now owns 4,974 shares of the technology company’s stock worth $159,000 after acquiring an additional 1,343 shares during the last quarter. Finally, The Manufacturers Life Insurance Company grew its position in shares of Simulations Plus by 7.7% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 6,391 shares of the technology company’s stock valued at $311,000 after acquiring an additional 456 shares during the period. Institutional investors own 78.08% of the company’s stock.

About Simulations Plus

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.